Dr. Jukka-Pekka Mecklin

Claim this profile

Tampere University Hospital and Tampere University

Studies Postprandial Fullness Syndrome
Studies Lynch Syndrome
1 reported clinical trial
2 drugs studied

Area of expertise

1Postprandial Fullness Syndrome
Jukka-Pekka Mecklin has run 1 trial for Postprandial Fullness Syndrome. Some of their research focus areas include:
MLH1 positive
MSH2 positive
MSH6 positive
2Lynch Syndrome
Jukka-Pekka Mecklin has run 1 trial for Lynch Syndrome. Some of their research focus areas include:
MLH1 positive
MSH2 positive
MSH6 positive

Clinical Trials Jukka-Pekka Mecklin is currently running

Image of trial facility.

Urine Tumor DNA Test

for Lynch Syndrome

Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently needed to identify LS-related cancers early enough for curative treatment. Urothelial cancers (comprising bladder and upper tract urothelial tumors) are the third most common cancer after colorectal and endometrial cancers in individuals with LS. Up to one in four LS individuals will develop urothelial cancer during their lifetime, with the risk varying based on the defective MMR gene. In this clinical trial, we will employ urine tumor DNA (utDNA) to identify asymptomatic urothelial cancers in Lynch syndrome patients, and to investigate the potential benefits of urine tumor DNA based screening in this high-risk population.
Recruiting1 award N/A

More about Jukka-Pekka Mecklin

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Jukka-Pekka Mecklin has experience with
  • Urothelial Cancer Screening Using Urine Cytology
  • Urothelial Cancer Screening Using Urine Tumor DNA Test
Breakdown of trials Jukka-Pekka Mecklin has run
Postprandial Fullness Syndrome
Lynch Syndrome
Bladder Cancer
Colorectal Cancer

Other Doctors you might be interested in

Jussi NikkolaTampere University Hospital and Tampere University
Toni SeppäläTampere University Hospital and Tampere University
Matti AnnalaTampere University Hospital and Tampere University

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jukka-Pekka Mecklin specialize in?
Jukka-Pekka Mecklin focuses on Postprandial Fullness Syndrome and Lynch Syndrome. In particular, much of their work with Postprandial Fullness Syndrome has involved MLH1 positive patients, or patients who are MSH2 positive.
Is Jukka-Pekka Mecklin currently recruiting for clinical trials?
Yes, Jukka-Pekka Mecklin is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Jukka-Pekka Mecklin has studied deeply?
Yes, Jukka-Pekka Mecklin has studied treatments such as Urothelial cancer screening using urine cytology, Urothelial cancer screening using urine tumor DNA test.
What is the best way to schedule an appointment with Jukka-Pekka Mecklin?
Apply for one of the trials that Jukka-Pekka Mecklin is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top